

Heart Failure Clinic and Professional Practice and Education Presents

The 19th Annual Heart Failure Symposium Wednesday, September 17, 2025

7:30 a.m. – 4:15 p.m.

Registration: 7:30 a.m.

Program starts promptly at: 7:55 a.m.

The Piedmont Club 361 E. Main St. Spartanburg, SC

AGENDA

7:30 a.m.	Registration, Exhibits, Continental Breakfast	
7:55	Welcome, Introductions	
8:00	I. The Role of Echocardiography in the Evaluation and Treatment of Heart Failure	Shane Reighard, MD
8:45	II. That's Not the Way It's Supposed to Flow! Transcatheter Treatments for Regurgitation	Kim Valenti, MSN, FNP-C
9:30	Break, Exhibits	
9:45	III. Heart-Felt Benefits: The Role of GLP-1 Receptor Agonists in Heart Failure Management	Caroline Emery, PharmD
10:45	IV. ATTR Amyloidosis – An Overlooked Patient Experience	James Ampadu, MD
	1. Mike Lane	
	2. Art Still	
12:15 p.m.	Lunch (provided), Exhibits	
1:15	V. Pulmonary Hypertension and Heart Failure	Ikenna Onyebueke, MD
2:00	VI. RV Failure – The Silent Killer	Ryan Lapointe, MD
2:45	Break, Exhibits	
3:00	VII. Advanced Heart Failure: Referral Timing and Case Studies	Amanda Green, MSN, AGACNP-BC, FNP-C, APRN
4:00	Wrap-up, Questions, Evaluations	
4:15	Adjourn	

LEARNING OUTCOMES/OBJECTIVES

At the end of the educational activity, 90% of attendees will be able to:

- Describe the role of echocardiography in the treatment of heart failure
- II. Discuss the role of the heart team in managing heart failure patients eligible for transcatheter valve therapies
- Explain the role of GLP-1 receptor agonists in the management of heart failure III.
- IV. Discuss the diagnosis and treatment for ATTR Amyloidosis
- ٧. Identify the diagnosis and treatment for pulmonary hypertension and heart failure
- VI. Recognize treatment modalities for RV failure
- VII. Review the impact of patient outcome on referral timing and case studies

TARGET AUDIENCE

Nurses, pharmacists, physician assistants, nurse practitioners, respiratory therapists, registered dietitians, rehab (PT/OT), long term care administrators and other interested healthcare professionals.

CONTINUING EDUCATION CREDIT (Accreditation Statement)

You must attend 90% of each of the educational sessions to receive CE credit.

Nurses

This educational activity has been awarded **6.75** contact hours.

SRHS Professional Practice & Continuing Education is approved as a provider of nursing continuing professional development by the South Carolina Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Respiratory Therapists, Registered Dietitians, Physical Therapists, Occupational Therapists

Can avail the approved nursing CE credit.

Long Term Care Administrators (Pending)

The program has been approved for	hours of continuing education by the South Carolina Board of Long Term
Health Care Administrators. Approval #	

Registered Pharmacists



The University of South Carolina College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The target audience for these continuing education activities is pharmacists. Please see individual activity listings on pages 4-5 below for specific information about CEU designations, learning objectives, and activity types.

To claim CE credit, participants must sign-in/register, participate in all active learning activities, respond to all learning assessment questions, and complete the online evaluations of each activity at https://cop.sc.learningexpressce.com to obtain credit. Detailed instructions on how to claim CPE credit will be provided. Completion of evaluations within 30 days of the program will ensure credit is transmitted; any credit claimed greater than 60 days after the conclusion of the program will not be accepted by the NABP CPE Monitor.

REGISTRATION FEES

- \$100.00 Nurses, RDs, RRTs, Rehab, LTC Administrator
- \$130.00 Pharmacists, PAs, NPs
- \$5.00 Additional fee after September 3

Registration fees include continental breakfast, lunch, and online handouts. Refunds are not allowed.

Online Registration: www.spartanburgregional.com/CEEvents

• Click on 19th Annual Heart Failure Symposium

Direct Link: https://www.eventbrite.com/e/19th-annual-heart-failure-symposium-tickets-1325772203349

SPEAKERS

James Ampadu, MD	Amanda Green, MSN, AGACNP-BC, FNP-C, APRN	
Advanced Heart Failure Director	Advanced Heart Failure, Transplant, VAD Nurse	
Prisma Health Medical Group-Midlands 6	Practitioner	
Columbia, SC	Sanger Heart and Vascular Institute	
	Atrium Health, Charlotte, NC	
Caroline Emery, PharmD		
Clinical Pharmacist, Prisma Health Cardiology		
Columbia, SC		

Spartanburg Regional Healthcare System, Spartanburg Medical Center

Ryan Lapointe, MD, MS	Shane Reighard, MD, MS	
Critical Care Physician	Non-invasive Cardiologist	
Director of system-wide resuscitation committee		
Ikenna Onyebueke, MD, FCCP	Kim Valenti, MSN, FNP-C	
Chief of Division, Pulmonary Medicine	Structural Heart Nurse Practitioner	

PLANNING/ADVISORY COMMITTEE

Spartanburg Regional Healthcare System

Greta Beach, BSN, RN	Michelle McCowan, BSN, RN
Patient Outreach RN, Heart Failure Clinic	Nurse Manager, 5H
Sherry Eison, DNP, MSN, APRN, FNP-BC	Deb McClennan, BSN, RN
Manager, Professional Practice & Continuing Education	Nurse Manager, 4Heart
Nelda M. Hope, BSN, RN	Jennifer T. Smith, MSN, BSN, RN
CE Coordinator,	Manager, Cardiovascular Accreditations, Program
Professional Practice & Continuing Education	Outreach & Clinical Analytics
Meghan Humphries, BSHA	Tiffany Vaughn, BSN, RN
Nursing Operations Coordinator	Nurse Navigator, Heart Failure Clinic
Nikki Ivey, BSN, RN	Jennifer Vigodsky, MSN, RN
UMC Stress Lab & Heart Failure Clinic	Nurse Manager, Heart Failure Clinic

Dr. James Ampadu reports the following relevant disclosures: speaker and consultant for Alnylam Pharmaceuticals and AstraZeneca Pharmaceuticals, as well as an advisory board member and consultant for BridgeBio Pharmaceuticals.

Dr. Ikenna Onyebueke reports the following relevant disclosure: speaker for Verona Pharma.

All other faculty, and planning committee report no financial relationship with any ineligible company.

CE approval does not imply endorsement of any product.

ADA

SRHS is committed to complying fully with the Americans with Disabilities Act.

For special needs, please send an email to sherry.eison@srhs.com or nhope@srhs.com by September 3.

THE PIEDMONT CLUB DRESS CODE (lunch)

Men: Gentlemen are not required to wear a jacket or tie.

Women: Suit (including business pantsuit), dress or blazer with skirt or tailored slacks, tailored pants with a blouse or sweater.

Prohibited: T-Shirts, sweatshirts, or other shirt without collar; athletic attire, tennis shoes, shorts, jeans (regardless of value), denim jackets, untucked shirts and baseball caps.

REMINDERS

- Sign-in for:
 - Pharmacists for ACPE credit
 - Nurse Practitioners and Physician Assistants if paid for ACPE credit
 - Long Term Care Administrators (LTC)
- Provided Name Badge must be always worn
- CE Instructions will be distributed at the end of the program
- Cell phones, other electronic devices: please silence your devices and refrain from using them during the program. Phone calls must be made outside of the building
- Restrooms located outside of the conference room
- Continental breakfast, refreshments and lunch are provided as scheduled
- Door Prizes: you must be present to win

ADDITIONAL INFORMATION

Registrants will receive an e-mail about 2-3 days before the event with additional information

QUESTIONS

Sherry Eison sherry.eison@srhs.com or Nelda M. Hope nhope@srhs.com or Nelda M. Hope nhope@srhs.com

ACPE ACTIVITY ANNOUNCEMENT

Wednesday, September 17, 2025		
l.	The Role of Echocardiography in the Evaluation and Treatment of Heart Failure	
	Shane Reighard, MD; Cardiologist- Medical Group of the Carolinas	
	ACPE UAN 0062-9999-25-092-L01-P, 0.75 contact hours, knowledge-based activity	
	At the completion of this activity, the participant will be able to:	
	Discuss the ACC/AHA recommendations regarding ECHO imaging in heart failure Discuss the relevant echocardiographic information for patients being treated for heart failure	
	3. Describe new ECHO technologies that will aid in the diagnosis and treatment of heart failure 3. Describe new ECHO technologies that will aid in the diagnosis and treatment of heart failure	
II.	That's Not the Way It's Supposed to Flow! Transcatheter Treatments for Regurgitation	
	Kimberly W. Valenti, MSN, APRN, FNP-C; Structural Heart Nurse Practitioner, Spartanburg Medical Center	
	ACPE UAN 0062-9999-25-093-L01-P, 0.75 contact hours, application-based activity	
	At the completion of this activity, the participant will be able to:	
	Explain the relationship between congestive heart failure and mitral/tricuspid valve regurgitation on heart failure progression	
	2. Identify patients with heart failure who are appropriate candidates for MitraClip or TriClip based on echocardiographic	
	findings and guideline recommendations	
	3. Describe current research and evolving role of transcatheter valve repair in heart failure management	
III.	Heart-Felt Benefits: The Role of GLP-1 Receptor Agonists in Heart Failure Management	
	Caroline Emery, PharmD; Clinical Pharmacist - Outpatient Cardiology, Prisma Health Richland	
	ACPE UAN 0062-9999-25-094-L01-P, 1.0 contact hours, application-based activity	
	At the completion of this activity, the participant will be able to:	
	1. Describe the mechanism of action of GLP-1 receptor agonists and their cardiovascular effects 2. Summarize the current clinical evidence supporting the use of GLP-1 receptor agonists in patients with heart failure, with	
	or without diabetes	
	3. Apply guideline-based evidence to optimize therapy in patient cases	

	ATTD Available in An Overdagled Deticut Forguing
IV.	ATTR Amyloidosis - An Overlooked Patient Experience
	James Ampadu, MD; Medical Director for Heart Failure and LVAD Program, Prisma Health
	ACPE UAN 0062-9999-25-095-L01-P, 1.50 contact hours, knowledge-based activity
	At the completion of this activity, the participant will be able to:
	1. Discuss the presentation and diagnosis of ATTR amyloidosis
	2. Identify the patient populations at risk for ATTR amyloidosis
	3. Discuss treatments for ATTR amyloidosis
	From Diagnosis to Treatment: A comprehensive view of Pulmonary Hypertension
	Ikenna Onyebueke, MD, FCCP; Chief of Pulmonary Medicine, Spartanburg Medical Center
	Attending Pulmonologist, Lung and Chest Medical Associates
	ACPE UAN 0062-9999-25-096-L01-P, 0.75 contact hours, application-based activity
.,	At the completion of this activity, the participant will be able to:
V.	1. Differentiate the pathophysiologic mechanisms and classifications of pulmonary hypertension, including the five WHO groups and hemodynamic subtypes
	2. Identify causes, risk factors, and comorbid conditions associated with the development of pulmonary hypertension
	3. Recognize clinical signs, symptoms, and diagnostic findings that support the identification of pulmonary hypertension
	4. Evaluate current treatment strategies for pulmonary hypertension, including general measures and targeted therapies,
	to support appropriate patient referral and management
	RV Failure - The Silent Killer
	Ryan Lapointe, MD, MS; Attending Physician - Critical Care Medicine, Spartanburg Medical Center
	ACPE UAN 0062-9999-25-097-L01-P, 0.75 contact hours, knowledge-based activity
VI.	At the completion of this activity, the participant will be able to: 1. Define RV failure
	2. Recognize RV failure based on clinical exam findings
	3. Differentiate Septic vs Cardiogenic Shock based on POCUS findings
	4. Identify treatment modalities for RV failure
	Advanced Heart Failure: Referral Timing and Case Studies
	Amanda Green, MSN, AGACNP-BC, FNP-C; Nurse Practitioner, Sanger Heart and Vascular Institute/Heart Failure
	ACPE UAN 0062-9999-25-098-L01-P, 1.0 contact hours, application-based activity
	At the completion of this activity, the participant will be able to:
VII.	1. Identify current gaps in the timing of referrals to heart failure clinics and their impact on patient outcomes across all stages of heart failure
	2. Recognize the clinical benefits of timely and appropriate referrals to specialized heart failure care, including improved
	patient management and outcomes
	3. Apply evidence-based guidelines and best practices to optimize referral timing and decision-making for patients with
	heart failure

7/30/25